AIM: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC). METHODS: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients. RESULTS: ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P<0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P<0.05). CONCLUSION: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine.
AIM: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC). METHODS: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the humancolorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients. RESULTS:ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P<0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P<0.05). CONCLUSION: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine.
Authors: H Boon; M Stewart; M A Kennard; R Gray; C Sawka; J B Brown; C McWilliam; A Gavin; R A Baron; D Aaron; T Haines-Kamka Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Gillian Smith; Francis A Carey; Julie Beattie; Murray J V Wilkie; Tracy J Lightfoot; Jonathan Coxhead; R Colin Garner; Robert J C Steele; C Roland Wolf Journal: Proc Natl Acad Sci U S A Date: 2002-07-01 Impact factor: 11.205
Authors: Hannah K Weir; Michael J Thun; Benjamin F Hankey; Lynn A G Ries; Holly L Howe; Phyllis A Wingo; Ahmedin Jemal; Elizabeth Ward; Robert N Anderson; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2003-09-03 Impact factor: 13.506
Authors: S Ohwada; T Ikeya; T Yokomori; T Kusaba; T Roppongi; T Takahashi; S Nakamura; S Kakinuma; S Iwazaki; H Ishikawa; S Kawate; T Nakajima; Y Morishita Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640
Authors: D Arango; J M Mariadason; A J Wilson; W Yang; G A Corner; C Nicholas; M J Aranes; L H Augenlicht Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640
Authors: David H Murray; Erin L Symonds; Graeme P Young; Susan Byrne; Philippa Rabbitt; Amitesh Roy; Kathryn Cornthwaite; Christos S Karapetis; Susanne K Pedersen Journal: J Cancer Res Clin Oncol Date: 2018-07-10 Impact factor: 4.553
Authors: V Thewes; R Simon; M Hlevnjak; M Schlotter; P Schroeter; K Schmidt; Y Wu; T Anzeneder; W Wang; P Windisch; M Kirchgäßner; N Melling; N Kneisel; R Büttner; U Deuschle; H P Sinn; A Schneeweiss; S Heck; S Kaulfuss; H Hess-Stumpp; J G Okun; G Sauter; A E Lykkesfeldt; M Zapatka; B Radlwimmer; P Lichter; M Tönjes Journal: Oncogene Date: 2017-03-20 Impact factor: 9.867
Authors: Martje Tönjes; Sebastian Barbus; Yoon Jung Park; Wei Wang; Magdalena Schlotter; Anders M Lindroth; Sabrina V Pleier; Alfa H C Bai; Daniela Karra; Rosario M Piro; Jörg Felsberg; Adele Addington; Dieter Lemke; Irene Weibrecht; Volker Hovestadt; Claudio G Rolli; Benito Campos; Sevin Turcan; Dominik Sturm; Hendrik Witt; Timothy A Chan; Christel Herold-Mende; Ralf Kemkemer; Rainer König; Kathrin Schmidt; William-Edmund Hull; Stefan M Pfister; Manfred Jugold; Susan M Hutson; Christoph Plass; Jürgen G Okun; Guido Reifenberger; Peter Lichter; Bernhard Radlwimmer Journal: Nat Med Date: 2013-06-23 Impact factor: 53.440
Authors: Judith M de Bont; Johan M Kros; Monique M C J Passier; Roel E Reddingius; Peter A E Sillevis Smitt; Theo M Luider; Monique L den Boer; Rob Pieters Journal: Neuro Oncol Date: 2008-06-24 Impact factor: 12.300
Authors: Seong-Su Han; Van S Tompkins; Dong-Ju Son; Natalie L Kamberos; Laura L Stunz; Ahmad Halwani; Gail A Bishop; Siegfried Janz Journal: Biochem Biophys Res Commun Date: 2013-06-11 Impact factor: 3.575